Safety, tolerability, pharmacokinetics and pharmacodynamics of a single intravenous dose of SHR‐1707 in healthy adult subjects: two randomized, double‐blind, phase 1 studies
Hu W, Shakib S, Williams J, Fan Y, Zhang Q, Qin H, Wu J, Zhang X, Liu Y, Zhou R, Yang Y, Zhang Q, Ye Z, Qiu H, Ma J, Zhu M, Feng S, Fei Y, Li N, Cui X, Dong F, Wang T. Safety, tolerability, pharmacokinetics and pharmacodynamics of a single intravenous dose of SHR‐1707 in healthy adult subjects: two randomized, double‐blind, phase 1 studies. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.074758.Peer-Reviewed Original ResearchPhase 1 studySingle intravenous doseHealthy young adultsPK/PD profilesHealthy adult subjectsIntravenous doseElderly subjectsYoung adultsDose levelsPD profilesAdult subjectsDose-proportional mannerPK/pharmacodynamicsFurther clinical developmentDose-dependent increaseSame dose levelIgG1 monoclonal antibodyPlacebo groupLaboratory abnormalitiesMicroglial phagocytosisAβ plaquesPreclinical studiesSHRClinical developmentAβ42 concentrations